TrialPath
Recruiting

Insulin and Insulin Pulses During Fasting

NCT06424015 · Mayo Clinic
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Effect of Insulin and Insulin Pulses on Fasting Glucagon Secretion and on Glucose Metabolism in Subjects Without Type 2 Diabetes
About this study
Decreased insulin action increases glucagon concentrations. In rodents, insulin signaling restrains glucagon secretion. It is unclear if this is the case in all (subtypes of) prediabetes. Impaired hepatic insulin action exacerbates glucagon's effects on endogenous glucose production. Also, insulin resistance in the β-cell impairs negative feedback inhibition of insulin secretion. This leads to hyperinsulinemia in rodents and humans. How these variables interact is unknown. This experiment will determine how insulin variably regulates fasting glucagon (and insulin) secretion directly, or indirectly, in prediabetes. The inability of the proinsulin to insulin ratio to reliably predict β-cell integrity, endoplasmic reticulum stress and β-cell function has led to the identification of novel markers of β-cell health. In addition, the relationship of glucagon and insulin pulses will be quantified. Preliminary data shows that there is heterogeneity in these relationships even in normal fasting glucose. Th experiment will also determine how islet hormone / glucose crosstalk and pulse characteristics contribute to prediabetes.
Eligibility criteria
Inclusion Criteria: * people with normal or impaired fasting glucose and normal or impaired glucose tolerance Exclusion Criteria: 1. HbA1c \> 6.5% 2. BMI ≥ 35 Kg/M2 3. Use of any glucose-lowering agents including metformin or sulfonylureas. 4. For female subjects: positive pregnancy test at the time of enrollment or study 5. History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy. 6. Active systemic illness or malignancy. 7. Symptomatic macrovascular or microvascular disease. 8. Hematocrit \< 35%
Study design
Enrollment target: 60 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2024-09-15
Estimated completion: 2027-09-01
Last updated: 2025-10-01
Interventions
Other: Intralipid and heparinOther: Saline
Primary outcomes
  • Suppression of Endogenous glucose production (EGP) by insulin (The rate of EGP at 240 minutes (end of study) expressed as a percentage of fasting EGP (at the start of the study i.e.: 0 minutes.)
  • Insulin pulse orderliness (Approximate Entropy (ApEn) will be calculated from the insulin concentrations observed every 2 minutes between -45 and 0 minutes)
Sponsor
Mayo Clinic · other
Contacts & investigators
ContactKim Osmundson, CCRP · contact · Osmundson.Kimberly@mayo.edu · 507-255-0907
ContactJeanette Laugen · contact · Laugen.Jeanette@mayo.edu · 507-255-8110
InvestigatorAdrian Vella, MD · principal_investigator, Mayo Clinic
All locations (1)
Mayo Clinic in RochesterRecruiting
Rochester, Minnesota, United States
Insulin and Insulin Pulses During Fasting · TrialPath